Alantra advised Cinfa on the sale of 3P Biopharmaceuticals to Keensight Capital
Alantra has advised Cinfa and the rest of the shareholders on the sale of 3P Biopharmaceuticals to Keensight Capital, a European Growth Private Equity Fund with deep expertise in Healthcare.
Founded in 2006 and based near Pamplona, Spain, 3P Biopharmaceuticals offers a complete biologics production service, from preclinical and clinical stages, all the way to full-scale commercial manufacturing. 3P develops and manufactures both new biological entities as well as biosimilars.
With more than 230 employees and a wide number of customers located in Europe, North America, Australia and Asia, 3P Biopharmaceuticals has successfully established itself as a recognized European CDMO leader. Benefiting from an increasingly international client base, constituted of highly regarded pharmaceutical and biotech companies, 3P has experienced a 23% annual revenue growth over the past 4 years. 3P’s manufacturing facility is both GMP certified as well as EMA and FDA approved.
This acquisition represents the third transaction advised to Cinfa in three years after the acquisitions of Sakura (Italy) and Natural Santé (France). The transaction also strengthens Alantra’s track record in the healthcare and biopharma segment.